期刊
CELL AND TISSUE RESEARCH
卷 384, 期 1, 页码 1-12出版社
SPRINGER
DOI: 10.1007/s00441-020-03364-w
关键词
Mesenchymal stem cells; Anthracycline-induced cardiotoxicity; Cardiac regeneration; Cardioprotectant; Doxorubicin
类别
资金
- Zhejiang Provincial Science and Technology Projects [GF20H020041, LGD19H160001]
- Shaoxing Municiple Science and Technology Projects [2018C30016]
- National Natural Science Foundation of China [81772537, 81374014]
MSC-based tissue regeneration therapy has shown promising protective and reparative effects against AIC, improving cardiac function and reducing inflammatory responses and myocardial fibrosis. The outcomes of MSC treatment for AIC are influenced by factors such as MSC types, dosages, and routes and duration of administration. Future research should focus on exploring the application of MSCs and their potential in cardiac regeneration.
Mesenchymal stem cell (MSC)-based tissue regeneration therapy has been extensively investigated for cardiac regeneration over the past two decades. Numerous animal and clinical investigations demonstrated the efficacy of various types of MSCs towards myocardial protection and restoration against anthracycline-induced cardiotoxicity (AIC). It has been established that local or systemic administration of MSCs considerably improved the cardiac function, while ameliorating inflammatory responses and myocardial fibrosis. Several factors influence the outcomes of MSC treatment for AIC, including MSC types, dosages, and routes and duration of administration. In this review, we discuss the recent (from 2015 to 2020) experimental and clinical research on the preventive and regeneration efficacy of different types of MSCs (with or without supporting agents) against AIC, as well as the key factors responsible for MSC-mediated cardiac repair. In addition, challenges and future perspectives of MSC-based cardiac regeneration therapy are also outlined.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据